Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

53.45
-1.3300-2.43%
Pre-market: 53.540.0900+0.17%08:25 EDT
Volume:1.18M
Turnover:63.83M
Market Cap:5.17B
PE:-11.23
High:54.90
Open:54.60
Low:53.31
Close:54.78
52wk High:78.48
52wk Low:44.12
Shares:96.69M
Float Shares:93.17M
Volume Ratio:1.06
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-26.09%
ROA:-14.20%
PB:2.96
PE(LYR):-8.26

Loading ...

CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T

Simply Wall St.
·
Jul 25

CRISPR Therapeutics (CRSP) Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns

Simply Wall St.
·
Jul 18

Crispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial

TIPRANKS
·
Jul 17

Crispr Therapeutics AG Slides Despite Bullish Wall Street

TIPRANKS
·
Jul 11

CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained

TIPRANKS
·
Jul 08

CRISPR Gene Editing Therapy Shows Groundbreaking Efficacy in Pediatric Patients

Deep News
·
Jun 30

HCA Healthcare announces research published in NEJM on CRISPR-based therapy

TIPRANKS
·
Jun 29

Week's Best: Spacex is Changing Market Indexes. ETF Investors, Take Note.

Dow Jones
·
Jun 27

Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts

TIPRANKS
·
Jun 24

Thanks to SpaceX, Index Funds Won't Track Each Other as Closely. Here's One Pro's Advice. -- Barrons.com

Dow Jones
·
Jun 23

Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts

TIPRANKS
·
Jun 13

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)

TIPRANKS
·
Jun 11

Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next

Simply Wall St.
·
Jun 07

Shareholders Approve New Incentive Plan and Governance Measures

TIPRANKS
·
Jun 05

CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Jun 04

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Simply Wall St.
·
May 29

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 28

Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial

TIPRANKS
·
May 23